Virtual care company Omada Health announced plans to start prescribing GLP-1s and other obesity drugs, expanding its weight management program for its growing membership of over 800,000. The move comes as digital health companies target the $100 billion market for GLP-1s to treat obesity, diabetes, and chronic conditions. Omada aims to support patients with lifestyle changes and help them manage medications, including potential side effects. The company’s new offering will provide crucial support for patients navigating GLP-1 treatments, offering guidance and coaching to improve health outcomes and control costs for health plans and employers. Omada Health, which went public in June, continues to grow its virtual care programs for chronic conditions like prediabetes, diabetes, and hypertension, positioning itself as a key player in the digital health landscape.

Read more at CNBC: Omada Health to start prescribing GLP-1s, other obesity medications